Summary
This 10-K filing for Johnson & Johnson (JNJ) for the fiscal year ending December 28, 2003, highlights a robust diversified healthcare company with strong positions across its consumer, pharmaceutical, and medical devices/diagnostics segments. The company operates globally, demonstrating resilience and a commitment to innovation through its ongoing research and development efforts. Investors can take comfort in JNJ's established market presence, ongoing patent protections, and compliance with rigorous regulatory standards, all of which contribute to its stable financial footing and long-term growth prospects. The filing indicates JNJ is an accelerated filer, signaling a mature and well-established reporting process.
Key Highlights
- 1Johnson & Johnson operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics, showcasing a diversified revenue base.
- 2The company holds strong market positions and relies on patents and trademarks to protect its intellectual property and product exclusivity.
- 3JNJ is subject to extensive regulation across all its business segments, which is a standard but significant aspect of its operating environment.
- 4The filing indicates a significant market capitalization, with approximately $153 billion in market value of common stock held by non-affiliates as of the second fiscal quarter.
- 5Research and Development (R&D) is a key focus, underscoring the company's commitment to innovation and future product pipelines.
- 6JNJ has a global operational footprint, with business activities and sales across various geographic areas.
Frequently Asked Questions
Johnson & Johnson operates across three principal business segments: Consumer, which includes well-known health and hygiene products; Pharmaceutical, focused on prescription drugs; and Medical Devices and Diagnostics, offering a range of surgical and diagnostic equipment.
The company relies significantly on patents and trademarks to protect its intellectual property. These legal protections are crucial for maintaining market exclusivity and supporting its research and development investments.
As of the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the common stock held by non-affiliates was approximately $153 billion.
While specific legal proceedings are not detailed in the provided excerpt, the filing notes that the company is subject to extensive regulation across all its business segments, which is a standard operational factor for a company of this nature in the healthcare industry.